VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of ...

Analysts anticipate Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.31. Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both ...

A recent decision from the United States District Court for the District of Columbia continues to give significant deference ...

It has been a week since the first round of the 2025 NFL Draft was completed, and while we all knew that the Tennessee Titans ...

Palantir stock has been a big winner in the software sector, helped by six straight quarters of accelerating revenue growth.

It's not every day that an NFL player rewrites the narrative of his trauma. The post Patrick Mahomes’ Mentor Reveals Painful ...

Vertex Pharmaceuticals is gearing up to drop its earnings on May 5, and the market’s popcorn is already popped. The company’s ...

Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...